Unlocking the Potential: Kura Oncology Unveils Promising Clinical Findings at ASH Annual Meeting for Menin Inhibitor Ziftomenib in KOMET-001 Trial
Unlocking the Potential: Kura Oncology Unveils Promising Clinical Findings at ASH Annual Meeting for Menin Inhibitor Ziftomenib in KOMET-001 Trial Description: – 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML – Low frequency of differentiation syndrome, including 5% rate (1/20) of ≥ Grade 3 among NPM1-mutant patients treated at 600…